Neurology

* Denotes subspecialty certified in Vascular Neurology, American Board of Psychiatry and Neurology

• Vani R. Chilukuri, MD, *Neurointensive care, clinical research, clinical care
• Larry B. Goldstein, MD, *Neuropharmacology, clinical research, health policy
• Carmelo Graffagnino, MD, *Neurointensive care, clinical research
• Jodi J. Hawes, MD, Neurorehabilitation
• Michael L. James, MD, Neuroanesthesiology/neurological critical care
• Brad J. Kolls, MD, PhD, *Neurointensive care, clinical research
• Daniel T. Laskowitz, MD, *Cell biology, neurointensive care
• E. Wayne Massey, MD, Clinical stroke care
• David McDonough, MD, Neuroanesthesiology/neurological critical care
• Joel C. Morgenlander, MD, Clinical stroke care
• Mark Skeen, MD, Clinical stroke care

Neuroendovascular Intervention

• Tony P. Smith, MD
• Gavin Britz, MD
• David Enterline, MD
• Ali Zomorodi, MD

Neurosurgery

• Allan H. Friedman, MD, Neurosurgery
• Takanori Fukushima, MD, Vascular neurosurgery

Interventional Cardiology

• J. Kevin Harrison, MD
• Cary C. Ward, MD

Vascular Surgery

• Richard L. McCann, MD

Diagnostic Neuroradiology

• James M. Provenzale, MD
• Daniel Barboriak, MD
• David Enterline, MD, Chief, Diagnostic Neuroradiology
• James Eastwood, MD
• Christopher Lascola, MD, PhD
• Linda Leithe, MD
• Jeffrey Petrella, MD

Coagulation Disorders/Thrombosis

• Thomas L. Ortel, MD, PhD
• Richard C. Becker, MD

Center for Clinical Health Policy Research

Web site: clinpol.mc.duke.edu

• David B. Matchar, MD, Director, Stroke prevention policy
• Gregory P. Samsa, PhD, Associate Director, Biostatistics
• Pamela W. Duncan, PhD, PT, Clinical trials, physical therapy, poststroke recovery

Duke Institute for Genome Sciences and Policy

Web site: genome.duke.edu

• David B. Goldstein, PhD, Genome Science

Duke Multidisciplinary Neuroprotection Laboratories

Web site: anesthesia.mc.duke.edu

• David S. Warner, MD, Director

The Multidisciplinary Neuroprotection Laboratories are dedicated to examining the pathophysiology of acute brain injury and defining therapeutic modalities for their treatment. Rodent models of focal and global cerebral ischemia, cardiopulmonary bypass, subarachnoid hemorrhage, and perinatal hypoxia/ischemia have been established with requisite control of relevant physiologic variables.

Experimental protocols examine effects of catalytic antioxidants, human apolipoprotein E isoforms, allosteric modifiers of hemoglobin/oxygen affinity, glutamate/glycine antagonists, and anesthetic agents on behavioral/histologic outcome. Neurochemical and molecular biological procedures are used to define drug/gene effects on biochemical sequelae to acute injury. Transgenic/knockout species are particularly important in this work. Primary neuronal/glial cultures are used to define cellular responses to oxidative and excitotoxic stresses with emphasis on supporting cell viability.

Researchers from both the basic and clinical neurosciences are integrated in this work.